The positive results seen in the 12 patients treated with the therapy, called etokimab, have led to a currently underway 300-person clinical trial.
The initial study, published in the journal Science Translational Medicine, is the first trial in humans to show that atopic dermatitis could be treated by targeting an immune signaling molecule called IL-33.
The trial was funded by the company AnaptysBio Inc. and led by researchers funded by UKRI’s Medical Research Council (MRC).
Read more (MRC WIMM website)